论文部分内容阅读
目的研究波棱甲素纳米混悬剂(PEDX-NS)的体内外抗乙肝病毒活性。方法本实验选择Hep G2 2.2.15细胞系和鸭乙肝病毒感染模型两种模型评价波棱甲素纳米混悬剂的体内外抗乙肝病毒活性,并与波棱甲素普通混悬剂(PEDX-CS)进行比较。结果体外实验结果显示,波棱甲素纳米混悬剂可有效抑制2.2.15细胞抗原(HBs Ag和HBe Ag)的分泌,并呈现一定的剂量依赖性,且波棱甲素纳米混悬剂的抑制作用显著高于波棱甲素普通混悬剂(P<0.05或P<0.01)。体内实验结果显示,高、中剂量(100、60 mg·kg-1)波棱甲素纳米混悬剂可显著降低鸭血清乙肝病毒-DNA的水平(P<0.05或P<0.01),且效果优于同剂量的波棱甲素普通混悬剂(P<0.05或P<0.01)。结论结果表明,波棱甲素纳米混悬剂体内外均具有抗乙肝病毒活性,且抗病毒作用明显优于波棱甲素普通混悬剂,其机制可能在于将其制成纳米混悬剂之后,粒径减小,表面积增大,体内吸收增加,从而使它的药效作用增强。
Objective To study the anti-hepatitis B virus (HBV) activity in vitro and in vivo of ribonucleic acid nano suspension (PEDX-NS). Methods In this study, two models of Hep G2 2.2.15 cell line and duck hepatitis B virus infection model were selected to evaluate the anti-hepatitis B virus activity of rifampicin nanosuspension in vitro and in vivo, CS) for comparison. Results The results of in vitro experiments showed that rifampicin nanosuspension could inhibit the secretion of 2.2.15 cell antigen (HBsAg and HBeAg) in a dose-dependent manner, and the effect of rifampicin nanosuspension The inhibitory effect was significantly higher than that of rifampicin common suspension (P <0.05 or P <0.01). In vivo experiments showed that high and medium dose (100,60 mg · kg-1) rifampicin nanosuspension can significantly reduce duck hepatitis B virus DNA level (P <0.05 or P <0.01), and the effect Better than the same dose of ribonucleic acid common suspension (P <0.05 or P <0.01). Conclusion The results showed that both hemiplegrom Nano-suspensions have anti-hepatitis B virus activity both in vitro and in vivo and the antiviral activity is superior to that of rifampin-A, which may be due to its nanosuspension, Reduced particle size, increased surface area, increased body absorption, so that its efficacy enhanced.